Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
On Tuesday, MAIA Biotechnology Inc (NASDAQ:MAIA) announced treatment updates from its Phase 2 THIO-101 trial of THIO sequenced with Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) cemiplimab (Libtayo) for advanced non-small-cell-lung-cancer patients who failed two or more standard-of-care therapy regimens.
The trial’s therapeutic regimen is cycled every three weeks, with THIO 180mg administered in 60mg incremental doses on days 1, 2 and 3, followed by immune activation on day 4 (no dosing), and cemiplimab 350mg administered on day 5.
As of the latest clinical cutoff date, June 12, 2024:
“Our longest treated patient so far has completed 21 cycles of THIO sequenced with a CPI, and six patients who have crossed the 12-month survival follow-up are continuing the treatment,” said Vlad Vitoc, chairman and chief executive officer of MAIA.
In June, MAIA Biotechnology shared new efficacy data from its Phase 2 THIO-101 study of THIO.
Updated results show a favorable overall response rate (ORR) of 38% and a disease control rate (DCR) of 85% from THIO + CPI in third-line treatment:
Price Action: MAIA stock is down 14.25% at $3.31 at last check Tuesday.
Read Next:
Image created using artificial intelligence via Midjourney.